Affiliation:
1. Department of Infectious Diseases , “Iuliu Hatieganu” University of Medicine and Pharmacy; Teaching Hospital of Infectious Diseases , Romania
2. Department of Immunology , “Iuliu Hatieganu” University of Medicine and Pharmacy , Romania
3. Department of Infectious Diseases , “Iuliu Hatieganu” University of Medicine and Pharmacy;Teaching Hospital of Infectious Diseases , Romania
Abstract
Abstract
Introduction: Community-acquired pneumonia (CAP) is the primary cause of severe sepsis. Severity assessment scores have been created, in order to help physicians decide the proper management of CAP. The purpose of this study was to examine the correlations between different CAP severity scores, including qSOFA, several biomarkers and their predictive value in the 30 day follow-up period, regarding adverse outcome.
Materials and methods: One hundred and thirty nine adult patients with CAP, admitted in the Teaching Hospital of Infectious Diseases, Cluj-Napoca, Romania from December 2015 to February 2017, were enrolled in this study. Pneumonia Severity Index (PSI), CURB-65, SMART-COP and the qSOFA scores were calculated at admittance. Also, C-reactive protein (CRP), procalcitonin (PCT) and albumin levels were used to determine severity.
Results: The mean PSI of all patients was 93.30±41.135 points, for CURB-65 it was 1.91±0.928 points, for SMART-COP it was 1.69±1.937 points. The mean qSOFA was 1.06±0.522 points, 21 (14.9%) were at high risk of in-hospital mortality. In the group of patients with qSOFA of ≥2, all pneumonia severity scores and all biomarkers tested were higher than those with scores <2. We found significant correlations between biomarkers and severity scores, but none regarding adverse outcome.
Conclusion: The qSOFA score is easier to use and it is able to accurately evaluate the severity of CAP, similar to other scores. Biomarkers are useful in determining the severity of the CAP. Several studies are needed to assess the prediction of these biomarkers and severity scores in pneumonia regarding adverse outcome.
Reference30 articles.
1. 1. Antunes G, Evans SA, Lordan JL, Frew AJ. Systemic cytokines levels in community-acquired pneumonia and their association with disease severity. Eur Respir J. 2002 Oct;20 (4):990–5. DOI: 10.1183/09031936.02.00295102
2. 2. Community-Acquired Pneumonia (CAP): Practice Essentials, Overview, Etiology of Community-Acquired Pneumonia [Online]. [2017] [cited February 2020]; Available from: URL: https://emedicine.medscape.com/article/234240-overview.
3. 3. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997 Jan;336(4):243–50. DOI: 10.1056/NEJM199701233360402
4. 4. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003 May;58(5):377–82. DOI: 10.1136/thorax.58.5.377
5. 5. [Online]. 2019 [cited February 2020]. Available from: URL: https://lifeinthefastlane.com/wp-content/uploads/2010/07/etg-smartcop.